# Novartis ends ALS program after phase 2 flop, adding to R&D woes

> **Open Intelligence Dossier** · First detected: 2026-09-16 19:00 UTC · Category: Business

## Executive Summary
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Novartis ends ALS program after phase 2 flop, adding to R&D woes" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.


Outlets currently covering the story include BioSpace. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOTjdHUGxsSFhMdXlIVkhvdEJKbHFXLXFBdF9Zb2lEdXllVXQzWmZ2ajRWVGlQUXBqOGtQWDBzRXZFUEt3ekxPMWtzUjBCcnROZUs4enNSS2s4QlVBbG50c1BSRGd1Sk1ZNHRLWXhhczNnVWhXUEtrOHNKM0x3WUxVbWFDMkE1SjJRQ04yLURiSk82TzJqUEZDRnREcURnT00zLXRNczR3X2JRazh1VkJrTlZnTnpmTzA?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-16/novartis-ends-als-program-after-phase-2-flop-adding-to-r-d-woes*